WO2024246565 - PHARMACEUTICAL COMPOSITION COMPRISING IBUPROFEN
National phase entry is expected:
Publication Number
WO/2024/246565
Publication Date
05.12.2024
International Application No.
PCT/GR2024/000014
International Filing Date
31.05.2024
Title **
[English]
PHARMACEUTICAL COMPOSITION COMPRISING IBUPROFEN
[French]
COMPOSITION PHARMACEUTIQUE COMPRENANT DE L'IBUPROFÈNE
Applicants **
TSETI, Ioulia
Inventors
TSETI, Ioulia
Priority Data
20230100444
02.06.2023
GR
20230100623
27.07.2023
GR
20230100733
13.09.2023
GR
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Natural Person
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2221 | |
| EPO | Filing, Examination, Granting | 7285 | |
| Japan | Filing, Examination, Granting | 2247 | |
| South Korea | Filing, Examination, Granting | 2325 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
18,818
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention refers to pharmaceutical compositions comprising ibuprofen or a pharmaceutically acceptable derivative thereof and one or more solubilizing agents in the form of A) aqueous solution for use in intravenous administration comprising ibuprofen of either the sodium or lysinate salt, paracetamol and preferably one or more cyclodextrins or B) aqueous solution for use in intravenous administration wherein the one or more solubilizing agents are one or more essential amino acids and optionally one or more cyclodextrins or C) composition for use in oral administration, which comprises paracetamol and cyclodextrin, wherein said composition is in the form of either i) effervescent tablets or effervescent granules or ii) oral suspension or syrup or oral solution or iii) soft capsules.[French]
La présente invention concerne des compositions pharmaceutiques comprenant de l'ibuprofène ou un dérivé pharmaceutiquement acceptable de celui-ci et un ou plusieurs agents solubilisants sous la forme de : A) une solution aqueuse destinée à être utilisée en administration intraveineuse comprenant de l'ibuprofène du sel de sodium ou de lysinate, du paracétamol et de préférence une ou plusieurs cyclodextrines ou B) une solution aqueuse destinée à être utilisée en administration intraveineuse, le ou les agents solubilisants étant un ou plusieurs acides aminés essentiels et éventuellement une ou plusieurs cyclodextrines ou C) une composition destinée à être utilisée en administration orale, qui comprend du paracétamol et de la cyclodextrine, ladite composition étant sous la forme soit i) de comprimés effervescents ou de granulés effervescents, soit ii) de suspension orale ou de sirop ou de solution orale, soit iii) de capsules molles.